Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040677 · ClinicalTrials.gov registry record · Phase 2

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

A Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Icagen.

Completed
Registry status
Phase 2
Development phase
90
Enrollment target
19
Study locations

NCT00040677 is a Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia that has completed, run by Icagen. The registered enrollment target is 90 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The trial reports 19 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00040677, a Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia, has completed, sponsored by Icagen.

COMPLETED
Registry status
Phase 2
Development phase
90 participants
Enrollment target
19
Study locations

Study Summary

ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and thus should prevent or delay the sickling process. By reducing sickled cells, an improvement in anemia, a reduction in painful crises, and ultimately, less end-organ disease is anticipated.

Conditions Studied

Sickle Cell Disease Sickle Cell Anemia

Interventions

  • DRUG Placebo
  • DRUG Low Dose ICA-17043
  • DRUG High dose ICA-17043

Study Locations (19)

California

  • Study Site - Oakland
  • Study Site - San Francisco

New York

  • Study Site - Brooklyn
  • Study Site - New York

North Carolina

  • Study Site - Chapel Hill
  • Study Site - Durham

Pennsylvania

  • Study Site - Philadelphia
  • Study Site - Pittsburgh

Alabama

  • Study Site - Birmingham

District of Columbia

  • Study Site - Washington D.C.

Georgia

  • Study Site - Augusta

Illinois

  • Study Site - Chicago

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2002-02
Est. Completion 2004-01
Phase Phase 2

Sponsor

Icagen

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00040677

The ClinicalTrials.gov registry entry for NCT00040677 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The listed sponsor is Icagen, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00040677 reports 19 study locations spanning 15 distinct geographic areas - top geographies include California, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00040677 about?

NCT00040677 is a clinical study titled "A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.". ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and t...

What is the current status of trial NCT00040677?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2002-02. Estimated completion is 2004-01.

What conditions does trial NCT00040677 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia.

What interventions are being tested in trial NCT00040677?

The interventions under investigation include: Placebo (DRUG), Low Dose ICA-17043 (DRUG), High dose ICA-17043 (DRUG).

Who is sponsoring clinical trial NCT00040677?

This trial is sponsored by Icagen, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00040677 being conducted?

This trial has 19 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Sickle Cell Anemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.